Introduction {#Sec1}
============

The ability of the hypothalamus to sense change in glucose levels is important in the control of feeding, energy expenditure and peripheral glucose homeostasis in mammals. Indeed, for patients with type 1 diabetes, the impairment of central detection of reduced glucose levels (hypoglycaemic unawareness) is a major concern, as this results in a defective counter-regulatory response, leading to severe risk of profound hypoglycaemia and consequent morbidities \[[@CR1]\]. Although brain glucose concentrations parallel those of plasma, they are generally much lower. Thus, during euglycaemia, brain glucose concentrations are \~1.0--2.5 mmol/l and, during extreme hyperglycaemia or hypoglycaemia, may reach 5 and 0.2 mmol/l, respectively \[[@CR2]\]. To detect changes in brain glucose levels and produce proportionate physiological responses, a neuronal glucose-sensing system is required. Brain regions intimately associated with this role are the hypothalamus, amygdala, basal ganglia and hindbrain, where specific neuron subtypes that respond electrically to acute variations in glucose are situated \[[@CR3]\]. The two major subtypes are glucose-excited (GE) and glucose-inhibited (GI) neurons, whereby a hypoglycaemic stimulus results in hyperpolarisation and inhibition and depolarisation and excitation, respectively \[[@CR3], [@CR4]\].

The identity of the molecular constituents that confer glucose-sensing properties on these neurons is unclear. This is due to the difficulties associated with intact brain tissue, absence of a transgenic mouse model allowing easy location of glucose-sensing neurons, uncertainties regarding the role of astrocytes, and lack of a suitable cell culture model. Although GE neurons exhibit similar glucose-sensing behaviour to pancreatic beta cells, the glucose concentration range over which electrical responses occur deviates significantly. The responsiveness of beta cells to altered plasma glucose is dependent on the presence of: GLUT2 in rodents (GLUT1 in humans), the high-capacity glucose transporter; GCK, the low-affinity hexokinase isoform, glucokinase; and K~ATP~, the ATP-sensitive K^+^ channel, consisting of the K^+^ channel subunit, K~ir~6.2, and the sulfonylurea receptor, SUR1 \[[@CR5]\]. All four proteins are produced in hypothalamic cells, but not always in a coincident manner and in conjunction with unequivocal identification of glucose-sensing properties \[[@CR6], [@CR7]\]. Thus there is no clear consensus about the molecular definition of glucose sensing in GE neurons. Our knowledge of the molecular constituents that underlie GI neuron glucose-sensing behaviour is even less well advanced \[[@CR8]\]. In addition, glucose sensing may not be an intrinsic feature of hypothalamic neuron populations, but may require metabolic support from glial cells, particularly astrocytes \[[@CR1], [@CR6]\].

Recent studies have shown that AMP-activated protein kinase (AMPK) is an essential component for detection of hypoglycaemia by pancreatic beta cells and hypothalamic neurons. Thus ablation of the AMPKα2 catalytic subunit from beta cells \[[@CR9]\] and subpopulations of GE hypothalamic neurons \[[@CR10]\] results in failure of these cells to respond electrically to reduced levels of glucose. Importantly, hypothalamic AMPK plays a key role in the integrative response to central hypoglycaemia detection, with AMPK downregulation suppressing \[[@CR11]\], and activation amplifying \[[@CR12]\], counter-regulatory responses, respectively.

We show that mouse hypothalamic GT1-7 cells \[[@CR13]\] exhibit hypoglycaemia-detecting behaviour typical of GE neurons and utilise a similar array of molecular components to beta cells to elicit an electrical response. Furthermore, like native hypothalamic neuron and beta cell glucose sensors, GT1-7 cells exhibit dependence on AMPKα2 activity for the transduction of a hypoglycaemic signal to an electrical response.

Methods {#Sec2}
=======

Cell culture {#d29e496}
------------

GT1-7 cells (Pamela Mellon, San Diego, California, USA \[[@CR13]\]) were maintained in DMEM (Sigma-Aldrich, Gillingham, UK) with 10% FBS (PAA Laboratories, Yeovil, UK) as previously described \[[@CR14]\].

Immunoblotting {#d29e507}
--------------

GT1-7 cells, in six-well dishes, were serum-starved for 3 h, and DMEM (low or high glucose) was replaced with normal saline (below) before challenge with glucose. Protein isolation and immunoblotting procedures were as described previously \[[@CR14]\]. Briefly, protein lysates were subjected to SDS-PAGE and electrotransferred to nitrocellulose membrane, and immunoreactive proteins were identified by chemiluminescence. Primary antibodies used were: phospho-AMPK (Thr172; 1:1000 dilution) and phosphorylated acetyl-CoA carboxylase (p-ACC; Ser79; 1:1000 dilution) from New England Biolabs, Hitchin, UK; AMPKα2 and AMPKα1 from D.G. Hardie, University of Dundee, Dundee, UK; GK from M. Magnusson, Vanderbilt University, Nashville, Tennessee, USA; K~ir~6.2 (p-Ser385) from L.M. Chuang, Taipei, Taiwan; actin (1:5000 dilution) from Sigma-Aldrich. Gel protein bands were quantified by densitometry, where total density was determined with respect to a constant area, the background was subtracted, and the average relative band density was calculated.

Assay of AMPK activity {#d29e518}
----------------------

GT1-7 cells were maintained in 2.5 mmol/l glucose/DMEM and serum and washed in normal saline (2.5 mmol/l glucose), before challenge with 2.5 or 0.5 mmol/l glucose for various times. Cells were lysed in lysis buffer (in mmol/l: 50 Tris-HCl, pH 7.5, 150 NaCl, 50 NaF, 5 sodium pyrophosphate, 1 EDTA, 1 EGTA, 1 dithiothreitol, 0.1 benzamidine) with 0.1 mmol/l phenylmethanesulfonyl fluoride, 5 μg/ml soya bean trypsin inhibitor and 1% (vol./vol.) Triton X-100, and the protein content was determined (BCA assay; Fisher Scientific, Loughborough, UK). AMPK activity was determined as previously described \[[@CR15]\] by calculating the difference in counts between AMARA (AMPK substrate: AMARAASAAALARRR)-containing and AMARA-negative samples as nmol ATP incorporated per min per mg peptide. Data were normalised to the control and are expressed as the mean of four to six independent experiments each with three replicates.

AMPK knockdown {#d29e526}
--------------

Lentiviral transduction of cells using non-targeting short hairpin RNA (shRNA; control; SHC202; Sigma-Aldrich) and shRNA targeting *Ampkα1* (also known as *Prkaa1*) and *Ampkα2* (also known as *Prkaa2*) was performed as per the manufacturer's instructions. Briefly, GT1-7 cells were grown in poly-[l-]{.smallcaps}lysine-coated 12-well dishes to \~50% confluence. Hexadimethrine bromide (10 μg/ml) and 40 μl lentiviral particles were added to each well, and, after 24 h, the mixture was replaced with fresh medium. Cells were grown to \~80% confluence and selected using puromycin hydrochloride (5 μg/ml). All data presented are from three to four independent cell lines, each generated in parallel to a control, and comparisons are between the knockdown line of interest and their control. Knockdown of AMPKα1 and AMPKα2 was screened by western blot and assay of radiolabelled kinase activity. A panel of five clones targeting AMPKα1 and AMPKα2 was used for screening, with clones XM_139298.4-1396s1c1 (AMPKα1) and XM_131633.3-858s1c1 (AMPKα2) providing the best knockdown.

Gene expression studies {#d29e546}
-----------------------

mRNA was quantified using real-time quantitative RT-PCR as described previously \[[@CR9], [@CR16]\]. mRNA was extracted from GT1-7 cells or mouse brain, heart or liver using Tri reagent (Sigma-Aldrich) according to the manufacturer's protocol. cDNA was prepared using 1 μg RNA reverse transcribed with Superscript II kit (Life Technologies, Paisley, UK) or ImProm-II reverse transcriptase (Promega, Madison, WI, USA) with oligo(dT) priming and RNase treatment. mRNA expression was analysed using an ABI Prism 7500 or ABI 7700 sequence detection system (Applied Biosystems, Foster City, CA, USA) or an iCycler iQ TM Multicolor Real-Time system (Bio-Rad, Hercules, CA, USA) using primer/probe sets designed (Applied Biosystems, Paisley, UK) to target *Slc2a1*, *Slc2a2*, *Slc2a3*, *Slc2a4* (solute carrier family 2 \[facilitated glucose transporters 1--4\]), *Hk1*, *Hk2*, *Hk3* and *Gck*, *Slc16a7* (neuronal monocarboxylate transporter), *Abcc8*, *Abcc9* (sulfonylurea receptors 1 and 2), and *Kcnj8* and *Kcnj11* (K~ir~6.1 and K~ir~6.2), and data were analysed by the $\documentclass[12pt]{minimal}
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                \begin{document}$$ {2^{ - \Delta {{\text{C}}_{\text{t}}}}} $$\end{document}$ method \[[@CR16]\]. Levels of *Ucp2* mRNA under control and AMPKα2 knockdown are expressed relative to 18S RNA. For detection of *Gck* mRNA, tissues were homogenised in Trizol reagent, and 1 μg RNA reverse transcribed as above. PCR was carried out with first-strand cDNA with primers for mouse pancreas-type GCK (forward, TGGAGGCCACCAAGAAGGAAAAG; reverse, GCATCTCGGAGAAGTCCCACGATG).

Electrophysiology {#d29e620}
-----------------

GT1-7 cells were superfused at room temperature (22--25°C) with saline (in mmol/l): 135 NaCl, 5 KCl, 1 MgCl~2~, 1 CaCl~2~, 10 HEPES, 10 or 2.5 glucose (pH 7.4). Membrane potentials were recorded using perforated-patch or whole-cell current-clamp configurations, and currents by whole-cell voltage clamp. In whole-cell experiments, cells were maintained in current-clamp mode to monitor resting membrane potential, with short excursions into voltage clamp to obtain current--voltage relations. Current- and voltage-clamp data were collected and analysed as described previously \[[@CR9]\]. Recording electrodes had resistances of 5--10 MΩ when filled with pipette solution, which for whole-cell recordings comprised (in mmol/l) 140 KCl, 5 MgCl~2~, 3.8 CaCl~2~, 10 EGTA, 10 HEPES, pH 7.2 (free \[Ca^2+^\] of 100 nmol/l). For perforated-patch recordings, the electrode solution contained (in mmol/l): 140 KCl, 5 MgCl~2~, 3.8 CaCl~2~, 10 HEPES, 10 EGTA (pH 7.2) and 25--40 μg/ml amphotericin B (Sigma-Aldrich). After a minimum of 10 min of stable recording, normal saline containing altered glucose concentration and/or tolbutamide (100 μmol/l), diazoxide (250 μmol/l) (both Sigma-Aldrich) or NN414 (5 μmol/l; Novo Nordisk, Copenhagen, Denmark) was applied.

Statistical analysis {#d29e650}
--------------------

Data are presented as means±SEM. Analysis of variance, one-sample *t* test and Student's paired or unpaired *t* tests were performed using GraphPad Prism (Prism 5) software (GraphPad Software, La Jolla, CA, USA). *p* values ≤0.05 were considered statistically significant.

Results {#Sec3}
=======

Expression of GT1-7 cell glucose transporter, hexokinase and functional K~ATP~ channel subunits {#d29e667}
-----------------------------------------------------------------------------------------------

GT1-7 cells show mRNA for the glucose transporters *Glut1*, *Glut3* and *Glut4*, but not *Glut2* (Fig. [1a](#Fig1){ref-type="fig"}) and for the monocarboxylate transporter, *Slc16a7* (data not shown). mRNAs for *Hk1* and *Hk2*, but not *Hk3* or *Gck*, could be distinguished (Fig. [1a](#Fig1){ref-type="fig"}). In further attempts to demonstrate *Gck* mRNA, PCR was performed using pancreas-specific *Gck* mRNA primers, and expression of this transcript was confirmed, with GCK protein also detectable by immunoblot in GT1-7 cells (Fig [1b,c](#Fig1){ref-type="fig"}). Sulfonylurea receptor subunit *Sur1* mRNA was expressed, with *Sur2b* mRNA also present, along with the pore-forming K~ATP~ subunit *K*~*ir*~*6.2* (with protein also detectable by immunoblot; electronic supplementary material \[ESM\] Fig. [1](#MOESM1){ref-type="media"}), although no *K*~*ir*~*6.1* or *Sur2a* mRNA was demonstrable (Fig. [1d](#Fig1){ref-type="fig"}). Perforated-patch recordings revealed electrical activity in saline containing 10 or 2.5 mmol/l glucose, with no difference in firing rates or membrane potential (*V*~m~) (10 mmol/l, *V*~m~ = −51.0 ± 2.5 mV \[*n* = 8\]; 2.5 mmol/l, *V*~m~ = −48.8 ± 2.2 mV \[*n* = 5\]; *p* \> 0.1). GT1-7 cells in 10 mmol/l glucose and challenged with 2.5 mmol/l glucose also showed no change in *V*~m~ or firing rate (data not shown). For cells in 2.5 mmol/l glucose, addition of tolbutamide (200 μmol/l) caused a modest depolarisation (\<3 mV) and increased firing (Fig. [1e](#Fig1){ref-type="fig"}). In contrast, the K~ATP~ activator, diazoxide (250 μmol/l), or the SUR1-specific activator \[[@CR17]\], NN414 (5 μmol/l), rapidly hyperpolarised *V*~m~ and inhibited firing (Fig. [1f,g](#Fig1){ref-type="fig"}). Whole-cell voltage clamp (Fig. [1h,i](#Fig1){ref-type="fig"}) showed significant K^+^ conductance, after washout of cell ATP, which was blocked by tolbutamide (200 μmol/l). These results indicate the presence of functional K~ATP~ channels in GT1-7 cells, which are predominantly closed at euglycaemic (2.5 mmol/l) glucose.Fig. 1GT1-7 cells express functional *K*~*ir*~*6.2*/*Sur1*-containing K~ATP~ channels. (**a**) Bar graphs showing cycle threshold for real-time PCR amplification of *Glut1*, *2*, *3* and *4*, *Hk1*, *2* and *3* and *Gck* mRNA from liver (grey bars), brain (hatched bars) and GT1-7 cells (black bars) (*n* = 3 for each). \# represents non-detectable. (**b**) Detection of brain/pancreas-type GCK by PCR and immunoblot in GT1-7 cells. DNA was extracted from different tissues (H, heart; B, brain; M, skeletal muscle; F, fat; L, liver; GT, GT1-7 cell line). La, DNA ladder. (**c**) Representative immunoblots for hexokinase (HK) and GCK in GT1-7 cells in comparison with mouse islets. (**d**) Bar graphs showing cycle threshold for real-time PCR amplification of *Sur1*, *Sur2a*, *Sur2b*, *K*~*ir*~*6.1* and *K*~*ir*~*6.2* from GT1-7 cells (*n* = 3 for each). (**e**) Perforated patch recording from GT1-7 cell showing excitation by tolbutamide (200 μmol/l). The bar graph shows mean values for membrane potential in 2.5 mmol/l glucose, in the absence (Cont) and presence (Tolb) of tolbutamide (*n* = 6). (**f**,**g**) Perforated patch recordings from GT1-7 cells in 2.5 mmol/l glucose showing the reversible hyperpolarisation in response to diazoxide (DZX) (**f**) and NN414 (**g**). Bar graphs denote mean values of membrane potential in cells exposed to diazoxide (*n* = 4) and NN414 (*n* = 4). (**h**) Representative current--voltage relationships for voltage-clamped currents of GT1-7 cells. Mean currents were measured at various membrane potentials shortly after attaining whole-cell recording (i.e. before significant washout of ATP (control; squares) and 20 min later (after maximal washout of cellular ATP \[0 ATP\], circles) and with subsequent addition of tolbutamide (200 μmol/l, triangles). (**i**) Bar graph denotes mean conductance density (*n* = 4) obtained under the recording conditions described in (**h**). Values are means±SEM. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001

Hypothalamic GT1-7 cells sense brain glucose concentrations {#d29e954}
-----------------------------------------------------------

In contrast with the lack of sensitivity over the physiological plasma glucose range (10--2.5 mmol/l) GT1-7 cells responded, reversibly, to a lower glucose concentration (0.5 mmol/l) by hyperpolarisation and cessation of firing, which occurred independently of the initial glucose concentration (Fig. [2a,b](#Fig2){ref-type="fig"}). This sensitivity was observed regardless of the glucose concentration in the culture medium. Thus, for GT1-7 cells maintained in 2.5 mmol/l glucose/DMEM, followed by 2.5 mmol/l glucose/saline, a reduction to 0.5 mmol/l glucose caused reversible hyperpolarisation (2.5 mmol/l, *V*~m~ = −46.8 ± 2.2 mV; 0.5 mmol/l, *V*~m~ = −61.3 ± 1.7 mV; *p* \< 0.001, *n* = 6) indistinguishable from cells maintained in high-glucose DMEM (Fig. [2a](#Fig2){ref-type="fig"}). GT1-7 cells responded to glucose concentrations below 1 mmol/l (Fig. [2c](#Fig2){ref-type="fig"}), in agreement with the glucose sensitivity reported for GE hypothalamic neurons \[[@CR10]\]. To address glucose sensitivity further, we used another mechanism that monitors cell energy availability \[[@CR18]\], AMPK, and examined phosphorylation of AMPK (p-AMPK) and its downstream effector, ACC (p-ACC). In GT1-7 cells exposed to 0.1 mmol/l glucose for 30 min and challenged with increasing glucose concentrations, maximal sensitivity occurred below 1 mmol/l (Fig. [2d](#Fig2){ref-type="fig"} and ESM Fig. [2](#MOESM2){ref-type="media"}). We also assessed AMPK phosphorylation in relation to hypoglycaemic glucose concentrations (2.5 mmol/l glucose starting point), which also demonstrates optimal sensing at concentrations below 0.5 mmol/l (Fig. [2e](#Fig2){ref-type="fig"}). As GT1-7 cells hyperpolarised to 0.5 mmol/l glucose (Fig. [2a](#Fig2){ref-type="fig"}), we were concerned that the immunoblot method was insufficiently sensitive. Consequently, direct AMPK activity assay showed that glucose reduction from 2.5 to 0.5 mmol/l significantly increased total AMPK activity after 15 min (Fig. [2f](#Fig2){ref-type="fig"}), when neuronal hyperpolarisation is maximal. In conclusion, the glucose concentrations that engendered the largest change in AMPK activity were between 1.0 and 0.1 mmol/l, in good agreement with the electrical sensitivity to hypoglycaemia.Fig. 2GT1-7 cells are sensitive to brain glucose concentrations. (**a**,**b**) GT1-7 cells respond, reversibly, to a reduction in glucose from 10 (**a**) or 2.5 (**b**) to 0.5 mmol/l by hyperpolarisation and cessation of firing. Bar graphs show mean values for membrane potential of cells exposed to 10 (**a**; *n* = 7) or 2.5 (**b**; *n* = 5) mmol/l glucose, or 0.5 mmol/l glucose and diazoxide (DZX). (**c**) Mean membrane potential values for GT1-7 cells as a function of glucose concentration (*n* = 5--7). (**d**) Representative immunoblot showing the effect of increasing glucose concentration (0.1--20 mmol/l) on p-AMPK and p-ACC levels. (**e**) Representative immunoblot showing the effect of glucose (0.1--2.5 mmol/l) on p-AMPK and total AMPK levels. Bar graph shows relative mean level of p-AMPK as a function of glucose concentration (*n* = 6). (**f**) AMPK activity (arbitrary units \[AU\]) measured in GT1-7 cells after their exposure to 2.5 and 0.5 mmol/l glucose for 15 min (*n* = 3). Values are means±SEM. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001

Glucose uptake and phosphorylation are required to maintain K~ATP~ closure in GT1-7 cells {#d29e1073}
-----------------------------------------------------------------------------------------

Expression studies showed mRNA for *Glut1*, *Glut3*, *Glut4* and hexokinase isoforms *Hk1*, *Hk2* and *Gck*. Cytochalasin B (20 μmol/l), an inhibitor of facilitated glucose transporters \[[@CR19]\], rapidly caused hyperpolarisation by opening K~ATP~, as denoted by tolbutamide reversal (Fig. [3a](#Fig3){ref-type="fig"}). The non-specific hexokinase inhibitor, alloxan (1 mmol/l), or replacement of glucose with the anti-metabolite, 2-deoxyglucose, also hyperpolarised GT1-7 cells (Fig. [3b,c](#Fig3){ref-type="fig"}). These results indicate that glucose uptake and metabolism are required to maintain the resting potential of GT1-7 hypothalamic neurons.Fig. 3Nutrient metabolism controls excitability of GT1-7 cells. (**a**) Perforated patch recording showing that cytochalasin B (Cyto B; 20 μmol/l) hyperpolarises GT1-7 cells in 2.5 mmol/l glucose, an action reversed by tolbutamide (200 μmol/l). Bar graph shows mean values for membrane potential of cells exposed to 2.5 mmol/l glucose (Cont), cytochalasin B and tolbutamide (Tolb; *n* = 5). (**b**) Alloxan (1 mmol/l) hyperpolarises GT1-7 cells. Bar graph shows mean membrane potentials under control conditions (2.5 mmol/l glucose) and in alloxan (*n* = 4). (**c**) Replacement of 2.5 mmol/l glucose with 2.5 mmol/l 2-deoxyglucose (2-DG) reversibly hyperpolarises GT1-7 cells. Bar graph denotes mean membrane potential of cells exposed to glucose and 2-deoxyglucose (*n* = 4). (**d**) Application of the GCK activator, GKA50 (1 μmol/l) reverses the hyperpolarisation and inhibition of firing caused by 0.5 mmol/l glucose. Bar graph shows mean membrane potential of cells exposed to 2.5 mmol/l glucose and 0.5 mmol/l glucose with or without GKA50 (*n =* 6). (**e**) Lactate compensates for low glucose in maintenance of GT1-7 cell membrane potential and excitability. Solid and broken lines denote glucose and lactate concentrations, respectively, with individual concentrations given above the trace. Bar graph shows mean membrane potential of cells in 0.1 mmol/l glucose (white bar) or lactate (0.1--3.0 mmol/l; *n* = 5--9; black bars). Values are means±SEM. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001

As *Gck* mRNA and protein abundance were low, we used an alternative approach to demonstrate that GCK contributed to glucose-sensing behaviour in GT1-7 cells. The GCK activator, GKA50, prevents hyperpolarisation of pancreatic beta cells in response to hypoglycaemic challenge \[[@CR9]\] and increases insulin secretion \[[@CR20]\]. After hyperpolarisation by 0.5 mmol/l glucose, application of GKA50 (1 μmol/l) caused depolarisation and increased firing (Fig. [3d](#Fig3){ref-type="fig"}), indicating increased glucose metabolic flux. Central neurons also metabolise lactate if their glucose supply is restricted \[[@CR21]\], thus we determined whether GT1-7 cells could use this alternative energy source to maintain *V*~m~ under hypoglycaemic conditions. GT1-7 cells exposed to 0.1 mmol/l glucose were depolarised when challenged with lactate at concentrations from 0.1 to 3.0 mmol/l (Fig. [3e](#Fig3){ref-type="fig"}). Although the mean changes in *V*~m~ induced by lactate only showed significance at 1.0 and 3.0 mmol/l, we observed cells that clearly responded to 0.3 mmol/l lactate (Fig. [3e](#Fig3){ref-type="fig"}).

Decreased AMPKα2, but not AMPKα1, activity diminishes the glucose sensitivity of GT1-7 cells {#d29e1196}
--------------------------------------------------------------------------------------------

The AMPKα2 subunit is required for hypoglycaemia sensing in pancreatic beta cells \[[@CR9]\] and subpopulations of hypothalamic neurons \[[@CR10]\]. Consequently, we examined whether this protein was also linked to glucose sensing in GT1-7 cells. To reduce AMPK levels and activity, GT1-7 cells were infected with lentivirus expressing shRNA to *Ampkα2* (sh*Ampkα2*), *Ampkα1* (sh*Ampkα1*) or a control, scrambled sequence (shCont). Immunoblots confirmed that both AMPK catalytic subunits were present, that treatment of GT1-7 cells with control vector had no effect on isoform protein levels, and that sh*Ampkα2* reduced AMPKα2, but not AMPKα1, protein levels (Fig. [4a](#Fig4){ref-type="fig"}). Measurement of AMPK isoform specific activity showed that GT1-7 cells exhibited predominantly AMPKα1 (0.395 ± 0.068 mU min^−1^ mg^−1^; *n* = 17) over AMPKα2 (0.0077 ± 0.0017 mU min^−1^ mg^−1^; *n* = 17) activity, and that 100 μmol/l H~2~O~2~ significantly raised the activity of both isoforms (Fig. [4b,d](#Fig4){ref-type="fig"}). Although sh*Ampkα2* treatment of GT1-7 cells did not significantly alter basal AMPKα2 activity (Fig. [4b,c](#Fig4){ref-type="fig"}), it did prevent H~2~O~2~ activation of AMPKα2, but not AMPKα1, activity (Fig. [4b,d](#Fig4){ref-type="fig"}) and importantly prevented stimulation of AMPKα2 activity by hypoglycaemia (Fig. [4c](#Fig4){ref-type="fig"}).Fig. 4AMPKα2 activity modifies GT1-7 sensitivity to hypoglycaemia. (**a**) Lentiviral delivery of shRNA targeting AMPKα2 reduces AMPKα2, but not AMPKα1, protein levels. Cells treated with control lentiviral vector (shCont) are unaffected. (**b**--**d**) sh*Ampkα2* prevents H~2~O~2~- (**b**) and low-glucose- (0.5 mmol/l; **c**) induced increase in AMPKα2 activity (arbitrary units \[AU\]), but has no effect (**d**) on H~2~O~2~-induced increase in AMPKα1 activity, (*n* = 4--7). White bars denote vehicle-treated cells and black bars H~2~O~2~-treated cells in (**b**) and (**d**), whereas in (**c**) white bars denote cells exposed to 2.5 mmol/l glucose and black bars cells exposed to 0.5 mmol/l glucose. (**e**) Representative recording showing the electrical response of GT1-7 cells infected with shCont to a reduction in glucose from 2.5 to 0.5 mmol/l and to application of NN414. Bar graph shows mean values for membrane potentials under the conditions described (*n* = 3--6). (**f**,**g**) GT1-7 cells infected with shAMPKα2 show no electrical response to 0.5 mmol/l glucose (**f**), but do respond to a more extreme hypoglycaemic (0.25 mmol/l glucose) stimulus (**g**). Bar graphs show mean values of membrane potential for shAMPKα2-treated GT1-7 cells challenged with 0.5 mmol/l (**f**; *n* = 6) and 0.25 mmol/l (**g**; *n* = 5) glucose. (**h**) Bar graph denotes mean conductance density under voltage clamp, in control (immediately after formation of stable clamp) and after a washout of ATP from the cell (20 min) for GT1-7 cells infected with shCont and shAMPKα2 lentivirus (*n* = 6--8). Values are means±SEM. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001

shCont-treated GT1-7 cells displayed electrical activity in 2.5 mmol/l glucose and responded to 0.5 mmol/l glucose by hyperpolarisation and cessation of firing (Fig. [4e](#Fig4){ref-type="fig"}) in a manner indistinguishable from untreated cells. In contrast, sh*Ampkα2*-treated cells were less responsive to hypoglycaemic challenge, with 0.5 mmol/l glucose having no effect on *V*~m~ or firing rate (Fig. [4f](#Fig4){ref-type="fig"}). However, these cells were responsive to more severe hypoglycaemic challenge, with 0.25 mmol/l (Fig. [4g](#Fig4){ref-type="fig"}) and 0.1 mmol/l (ΔV~Cont~ = −9.7 ± 2.1 mV; ΔV~shAMPKα2~ = −13.5 ± 4.3 mV; *n* = 4; *p* \> 0.1) glucose exposure causing hyperpolarisation. Thus treatment of GT1-7 cells with sh*Ampkα2* shifts the threshold for detection electrically to a more severe hypoglycaemia stimulus. This shift in glucose-sensing capability was not associated with any change in maximal K~ATP~ conductance of GT1-7 cells (Fig. [4h](#Fig4){ref-type="fig"}). As responsiveness to NN414 was also unaltered (compare Fig. [4e,f](#Fig4){ref-type="fig"} and Fig. [1g](#Fig1){ref-type="fig"}), it is likely that no change in K~ATP~ availability is associated with modification of glucose sensing. Sh*Ampkα1*-treated GT1-7 cells exhibited reduced AMPKα1 protein levels (Fig. [5a](#Fig5){ref-type="fig"}) and depressed H~2~O~2~-stimulated AMPKα1 activity (Fig. [5b](#Fig5){ref-type="fig"}), which was not associated with loss of AMPKα2 protein levels or activity. Furthermore, stimulation with H~2~O~2~ increased AMPKα2 activity, identical with the control (Fig. [5d](#Fig5){ref-type="fig"}). Although sh*Ampkα1* treatment of GT1-7 cells ablated stimulation of AMPKα1 activity by 0.5 mmol/l glucose (Fig. [5c](#Fig5){ref-type="fig"}), robust and reproducible hyperpolarising responses to 0.5 mmol/l glucose were observed (Fig. [5e](#Fig5){ref-type="fig"}), indicating that AMPKα2, rather than AMPKα1, activity is required for cells to respond electrically to hypoglycaemia.Fig. 5Hypoglycaemic responses are insensitive to reduction in AMPKα1. (**a**) Lentiviral delivery of shRNA targeting AMPKα1 reduces AMPKα1, but not AMPKα2, protein levels. Cells treated with control lentiviral vector (shCont) are unaffected. (**b**--**d)** shAMPKα1 reduces H~2~O~2~- (**b**) and 0.5 mmol/l glucose (**c**)-induced increase in AMPKα1 activity (arbitrary units \[AU\]), but has no effect (**d**) on H~2~O~2~-induced increase in AMPKα2 activity (*n* = 4--12). White bars denote vehicle-treated cells and black bars H~2~O~2~-treated cells in (**b**) and (**d**), whereas in (**c**) white bars denote cells exposed to 2.5 mmol/l glucose and black bars cells exposed to 0.5 mmol/l glucose. (**e**) GT1-7 cells infected with shAMPKα1 show a normal electrical response to 0.5 mmol/l glucose. Bar graph shows mean values of membrane potential for shAMPKα1-treated GT1-7 cells challenged with 0.5 mmol/l glucose and NN414 (*n* = 4--6). Values are means±SEM. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001

UCP2 may also contribute to glucose sensing in GT1-7 cells {#d29e1545}
----------------------------------------------------------

Previous work suggests a role for UCP2 in the glucose-sensing behaviour of beta cells and hypothalamic neurons \[[@CR22]--[@CR24]\], with K~ATP~ activation and hyperpolarisation induced by low glucose in beta cells and proopiomelanocortin (POMC) neurons prevented by pharmacological inhibition of UCP2 with genipin \[[@CR9], [@CR24]\]. In agreement, we found that genipin (100 μmol/l) prevented GT1-7 cells from responding electrically to hypoglycaemia (Fig. [6a](#Fig6){ref-type="fig"}). Furthermore, treatment of GT1-7 cells with sh*Ampkα2* significantly reduced *Ucp2* mRNA levels, in comparison with shCont-treated cells (Fig. [6b](#Fig6){ref-type="fig"}), suggesting a close link between AMPKα2 activity and UCP2 content.Fig. 6Reduction in UCP2 may link AMPK and glucose sensing in GT1-7 cells. (**a**) Representative recording showing the effects of genipin (100 μmol/l) on uninfected GT1-7 cells, in the presence of 0.5 mmol/l glucose. Bar graph shows mean values of membrane potential for cells in 2.5 mmol/l glucose and 0.5 mmol/l glucose with or without genipin (*n* = 5). (**b**) Treatment of cells with shAMPKα2 reduces UCP2 mRNA levels (*n* = 15--17). Values are means±SEM. \**p* \< 0.05, \*\*\**p* \< 0.001

Discussion {#Sec4}
==========

GT1-7 cells, which make and secrete gonadotrophin-releasing hormone (GnRH) exhibit intrinsic glucose-sensing properties after reduction of extracellular glucose from the euglycaemic levels (2.5 mmol/l) normally associated with brain. As reported here for GT1-7 cells, mouse GnRH neurons express mRNA for *Gck* and the K~ATP~ subunits *K*~*ir*~*6.2* and *Sur1*, and respond to lowered glucose by K~ATP~-dependent hyperpolarisation \[[@CR25]\]. Furthermore, *K*~*ir*~*6.2* and *Sur1* mRNAs have been demonstrated in hypothalamic GE neurons using single-cell RT-PCR \[[@CR7], [@CR26]\]. However, the presence of these transcripts did not completely correlate with GE neuron phenotype, and expression of the combination, *K*~*ir*~*6.1* and *Sur1*, has also been reported in hypothalamic GE neurons \[[@CR27]\]. Our findings that GT1-7 cells express *K*~*ir*~*6.2* and *Sur1*, but not *K*~*ir*~*6.1*, mRNA support the notion that the beta cell K~ATP~ subunit combination underlies GE neuron effector responses to hypoglycaemia. Demonstrable levels of K~ir~6.2 protein and K~ATP~ activation by diazoxide and NN414 and inhibition by tolbutamide also support this subunit permutation. In keeping with the proposed role for GCK as 'gatekeeper' of neuronal glucose sensing \[[@CR28], [@CR29]\], GCK inhibition by alloxan or activation by GKA50 \[[@CR20]\] mimicked or reversed the effects of hypoglycaemic challenge. These results indicate major roles for K~ATP~ and GCK in mediating glucose sensing in GT1-7 cells as described for pancreatic beta cells \[[@CR30], [@CR31]\]. In rodent beta cells, GLUT2 mediates glucose entry under physiological glucose concentrations \[[@CR32]\]. However, GT1-7 cells only expressed *Glut1*, *Glut3* and *Glut4* transcripts. GLUT2 is mainly located in astrocytes, with GLUT3 being the primary neuronal transporter, although GLUT1 and GLUT4 have been reported in neurons \[[@CR33]\]. Indeed, glial GLUT2 may be required for normal glucagon secretion in response to hypoglycaemia \[[@CR34]\]. GLUT1 and GLUT3 have low *K*~m~ values (\~1 mmol/l \[[@CR33]\]) consistent with the glucose sensitivity of hypothalamic GE neurons \[[@CR10], [@CR35], [@CR36]\] and GT1-7 cells. GLUT4 has a *K*~m~ that encompasses the physiological range of brain glucose and could allow insulin-mediated modulation of glucose uptake, as described for hypothalamic GE neurons \[[@CR37]\].

The lack of responsiveness to glucose above 2.5 mmol/l and the small effect of tolbutamide in 2.5 mmol/l glucose indicate that GT1-7 K~ATP~ channels are mostly closed in euglycaemic and hyperglycaemic conditions. This has previously been reported for GE neurons \[[@CR38]\], and contrasts with larger beta cell responses to tolbutamide under euglycaemic conditions, indicating the greater influence of K~ATP~ on the resting *V*~m~ of beta cells. Indeed, the baseline resting *V*~m~ of GT1-7 cells of \~ −50 mV is similar to that reported previously for hypothalamic GE neurons \[[@CR10], [@CR26], [@CR27], [@CR36], [@CR37], [@CR39]\]. In contrast, reducing the glucose concentration to 1.0 mmol/l or below caused reversible K~ATP~-dependent hyperpolarisation and reduction, or loss, of firing of GT1-7 cells. The sensitivity of GT1-7 *V*~m~ to agents that suppress glucose uptake and metabolism indicates the requirement, as observed for beta cells, for glucose entry and metabolism to maintain K~ATP~ in the predominantly closed conformation. Glial cells, such as astrocytes, provide neurons with energy substrates \[[@CR3]\] such as lactate, which, in conjunction with monocarboxylate transporters, cause closure of K~ATP~ in GE neurons \[[@CR39]\]. Thus astrocyte lactate production may act as an energy fuel reserve for neurons, maintaining their electrical activity during hypoglycaemia \[[@CR1]\]. Although GT1-7 cells are intrinsic glucose sensors, the presence of *Slc16a7* mRNA and the ability of exogenous lactate to depolarise and excite these cells under conditions of glucose deprivation indicate that lactate conversion into pyruvate in neurons could maintain their *V*~m~ and excitability during hypoglycaemic episodes. Indeed, the similar concentration response of lactate and glucose on *V*~m~ indicates that lactate is a more effective energy substrate, on an energy basis, at closing K~ATP~ channels. Consequently, GT1-7 cells behave as direct glucose and lactate sensors.

AMPK is an important nutrient sensor and effector mechanism in cells, allowing detection of lowered cell energy status with coupling to intrinsic cell mechanisms designed to restore energy balance. Changes in AMPK activity have been implicated in counter-regulatory hormone responses to hypoglycaemia \[[@CR11], [@CR12]\], and a role for AMPK has been proposed for hypoglycaemia-dependent depolarisation of hypothalamic GI neurons \[[@CR40], [@CR41]\]. In addition, deletion of the AMPKα2 catalytic subunit in beta cells \[[@CR9]\] and identified hypothalamic neurons \[[@CR10]\] prevents hypoglycaemic challenge from K~ATP~ activation and hyperpolarisation. Hypoglycaemia increases AMPK activity in GT1-7 cells with a glucose concentration-dependence that mirrors the electrical change. By using shRNA targeted to AMPKα subunits, we decreased protein levels of the targeted subunit sufficiently to reduce its maximal activation by H~2~O~2~ and prevent AMPKα activation by 0.5 mmol/l glucose. This demonstrated that reducing AMPKα2, but not AMPKα1, activity prevented the hyperpolarising response to 0.5 mmol/l glucose, but not to stronger stimuli, indicating a shift in the glucose-sensing threshold away from the physiologically relevant range. This result puts AMPKα2 activity (which is only \~2% of total AMPK activity in GT1-7 cells) directly in the glucose-sensing pathway of GE neurons.

Therefore, what links AMPKα2 activity with GE neuron metabolism and K~ATP~ channels? It is generally considered that modulation of beta cell K~ATP~ activity by glucose metabolism is driven by changes in the ATP/ADP ratio. Glucose sensing is negatively regulated by raised UCP2 activity, which is argued to diminish the yield of ATP from glucose, causing beta cell dysfunction \[[@CR23], [@CR42]\]. *Ucp2* is highly expressed in the hypothalamus \[[@CR43]\], and recent studies suggest that UCP2 negatively regulates glucose sensing in hypothalamic neurons \[[@CR24], [@CR44]\]. Increased UCP2 decreases mitochondrial *V*~m~ and respiration, via uncoupling, and is expected to reduce the ATP/ADP ratio, thus causing K~ATP~ opening. This scenario is supported by the observation that genipin closes K~ATP~ and depolarises beta cells and POMC neurons, and this requires the presence of UCP2 \[[@CR30], [@CR32]\]. Under hypoglycaemic conditions, genipin closes K~ATP~ and depolarises GT1-7 cells, suggesting a UCP2-mediated change in glucose metabolism in these cells. However, we have been unable to detect an alteration in bulk ATP/ADP during hypoglycaemia in GT1-7 cells (ESM Fig. [3](#MOESM3){ref-type="media"}), consistent with a previous study \[[@CR39]\] of GE neurons. It is plausible that localised, sub-membrane alterations of ATP/ADP are responsible for generating the signals that control K~ATP~ gating under hypoglycaemic conditions and our measures are simply insufficiently sensitive. Nevertheless, reducing AMPKα2 in GT1-7 cells significantly decreased *Ucp2* mRNA levels, an outcome also reported in islets from mice lacking AMPKα2 in beta cells \[[@CR9]\]. Thus AMPKα2 activity may, in an as yet undefined way, be positively linked to *Ucp2* transcription in GE neurons and pancreatic beta cells. Interestingly, activation of AMPK increases *Ucp2* expression in beta cells \[[@CR45]--[@CR47]\].

Our findings demonstrate that the GT1-7 cell line is an excellent model with which to probe hypothalamic glucose-sensing mechanisms. GT1-7 cells replicate the critical features of hypothalamic GE neurons, with functional expression of the molecular components essential for metabolic sensing and transduction to an electrical signal, as exemplified by beta cells. Decreasing AMPKα2 activity in GT1-7 cells diminished electrical sensitivity to a moderate hypoglycaemic stimulus, an action that may require reduced UCP2, although we have no definitive data to prove this at present. We hypothesise that AMPKα2 acts as a sensor of fluctuations in glucose concentration by connecting glucose metabolism, through modulation of UCP2, with changes in local nucleotide levels (e.g. ADP), K~ATP~ channel activity and electrical excitability (Fig. [7](#Fig7){ref-type="fig"}). Furthermore, it is possible that hormones such as leptin and/or amylin could, by modifying AMPK activity \[[@CR48]\], alter this intrinsic glucose-sensing behaviour. Functional deficits of any one of the classical components of glucose-sensing cells (e.g. K~ATP~, GLUT2 and GCK) engender dysfunctional output, as exemplified for pancreatic beta cells and type 2 diabetes \[[@CR30], [@CR49], [@CR50]\]. Consequently any loss of function involving AMPKα2--UCP2 in beta cells or GE neurons may have a similar outcome. Therefore, in the context of hypothalamic glucose sensing, it will be interesting to determine whether defective glucose counter-regulation after recurrent bouts of hypoglycaemia is associated with alterations in the putative hypothalamic AMPKα2--UCP2 pathway.Fig. 7Model of GT1-7 cell illustrating the molecular components indicative of a GE neuron. In order to correlate neuronal firing with glucose concentration, the cell must have a glucose-sensing and measuring system. This is denoted by the presence of the glucose-transport protein GLUT3 and glucokinase. (**a**) Glucose uptake and glucokinase activity are sufficient under euglycaemic conditions (2.5 mmol/l) to produce sufficient metabolic flux to maintain a high ATP/ADP ratio. This keeps AMPKα2 activity low (basal) and K~ATP~ channels predominantly in the closed conformation, thus maintaining a relatively depolarised membrane potential and regular firing (as illustrated by the inset figure). (**b**) If the cell is now exposed to a hypoglycaemic environment (e.g. 0.5 mmol/l glucose), there is reduced glucose metabolic flux, which results in a reduced ATP/ADP ratio (thought to be due to increased ADP, as phosphotransfer reactions maintain ATP levels). This rise in sub-plasma membrane ADP, in conjunction with increased AMPKα2 activity (possibly associated with increased UCP2 activity) causes increased K~ATP~ channel activity, resulting in cell hyperpolarisation and cessation of firing
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